Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: boxthefox, 21 Jun 2024 16:55
Last post: Winstanley, 21 Jun 2024 17:03
Strange, it's been flat-lining for ages, now it moves!
33 million shares sold today. What's the story?
Started: Mr.Picky, 5 Jun 2024 13:18
Last post: Mr.Picky, 5 Jun 2024 13:18
Berenberg starts Haleon with 'buy' - price target 407 pence
A rise of 24.8% (for what it is worth).
Started: MosquitoSqudron, 26 May 2024 18:39
Last post: Nomadme, 27 May 2024 11:25
Ooh, maybe see a nice rise on Tuesday with this news, I bought into Tate a few weeks ago and then they shot up on news they sold part of business to KPS.
Let’s see what happens.
Apparently, Indian pharmaceutical group is closing in on a deal to snap up Nicotinell, the anti-smoking aid, from Haleon https://news.sky.com/story/indian-pharma-group-readies-swoop-on-anti-smoking-aid-nicotinell-13143478
Started: meoryou, 17 May 2024 09:28
Last post: meoryou, 17 May 2024 09:28
Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.
Started: meoryou, 16 May 2024 20:45
Last post: meoryou, 16 May 2024 20:45
Sharecast News) - GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.
The pharmaceutical company will sell about 385m ordinary shares in consumer health business Haleon, which it spun off in July 2022.
GSK initially retained a 12.9% stake in Haleon, but has since sold stakes in May 2023, October 2023 and January 2024.
The final disposal will be conducted through a placing of ordinary shares to institutional investors. GSK said the offer price will be determined by means of an accelerated bookbuild offering process which will start immediately.
Is there any growth in this, what do you all think?
Started: Winstanley, 13 May 2024 20:51
Last post: Winstanley, 13 May 2024 20:51
Started: meoryou, 29 Feb 2024 07:44
Last post: Trickytree55, 30 Apr 2024 15:40
More 'cost saving measures'.
Maidenhead plant roles to be shed - approx 436 by 2026
Production of Sensodyne to be transferred to Slovakia
Haleon SP is high.
Final Div
Announce date 29-Feb-24 ex div 14-Mar-24 pay 16-May-24 4.2p
Total: 6.0p
FY net cash flow from operating activities was £2,100m, with Free cash flow of £1,575m
● Net debt at 31 December 2023 of £8,514m, with 3.0x net debt/adjusted EBITDA
● Proposed dividend payout of 35% (FY 2022: 30%); with a final dividend of 4.2p per ordinary share
● Going forward dividend to grow at least in line with adjusted earnings
● Announcing capital allocation of £500m for share buybacks in 2024
Within 18 months of our demerger, we reduced net debt by over £2 billion, bringing net debt/adjusted
EBITDA down from c.4x to 3x, reflecting both strong cash conversion and financial discipline, underpinning
an increased dividend payout and share buyback. Taken together, our results show consistent delivery on our financial commitments.
Started: meoryou, 22 Mar 2024 12:10
Last post: meoryou, 22 Mar 2024 12:10
This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").
Pfizer sold 594,000,000 Haleon ordinary shares and 196,554,820 ordinary shares in the form of American depositary shares, each representing two ordinary shares ("ADSs") pursuant to a global offer. In connection with the global offer, Haleon repurchased 102,272,727 ordinary shares from Pfizer in accordance with the terms of a share purchase deed between Haleon and Pfizer dated 11 September 2023 and approved by Haleon's shareholders at its annual general meeting on 20 April 2023.
These calculations are based on an issued share capital of Haleon of 9,132,301,104 ordinary shares, following cancellation of the 102,272,727 ordinary shares repurchased from Pfizer, as communicated by Haleon in their announcement on total voting rights and capital dated 21 March 2024.
Pfizer holds its ordinary shares in Haleon through (i) BofA Securities, Inc., and (ii) Guaranty Nominees Limited (in respect of the ADSs), which hold the legal title to those shares on Pfizer's behalf.
Started: meoryou, 19 Mar 2024 07:27
Last post: nomlungu, 19 Mar 2024 17:47
Boxthefox,
I think the general consensus is that Haleon is very sensitive to medium to long term interest rate changes. The FED and the BoE have taken longer than was first thought to start reducing rates; if / when they come down then expect the share price here to go in the reverse. From the last set of accounts:
'Consistent with the priorities set out at the time of listing, we have rapidly de-levered to 3.0x net debt/adjusted EBITDA as at 31 December 2023. Strong cash generation enabled us to accelerate debt repayment and we now expect to operate at leverage of around 2.5x over the medium-term. This underpinned our decision to announce a capital allocation of £500m for share buybacks in 2024.
Did I read that Haleon bought some of these at £3.08 to be cancelled? I may be wrong but would this not indicate that the share price might hang around at the £3.08 level for some time?
As a result of the Global Offer, the Share Buyback and cancellation, Pfizer's interest in Haleon will reduce from 32% to approximately 22.6% of Haleon's issued Ordinary Shares with rights to vote.
Haleon has agreed to repurchase 102,272,727 Ordinary Shares from Pfizer off-market, subject to the completion of the Global Offer, for aggregate consideration of approximately £315 million (approximately $400 million)
Haleon intends to cancel the purchased Ordinary Shares. Following the Share Buyback and such cancellation, the total number of Ordinary Shares issued by Haleon with rights to vote is expected to be 9,132,301,104, as compared to 9,234,573,831 Ordinary Shares with rights to vote today. No shares are held in treasury.
Started: casapinos, 18 Mar 2024 07:51
Last post: meoryou, 18 Mar 2024 13:24
That’s another major dent in the share overhang.
Other than the big 2, the other major shareholders appear to be 2% or less.
In my view it’s positive that Hln felt able to take part and buy back some as well.
It’s not the end of the share overhang,but think we are being showed it’s not a major problem,except to keep a lid on maximum sp.
It’s going to be interesting what happens to sp as the overhang shrinks away
Or... the company stands to benefit from a better interest rate environment later this year, and the listing of US ADSs will help negate the discount that UK stocks suffer from. Pfizer are unlikely to be doing a fire sale...
See
https://www.londonstockexchange.com/news-article/HLN/proposed-secondary-global-offering-by-pfizer-inc/16381099
I have said on several occasions that the split of the old GSK , left Haleon with two reluctant holders, ie Pfizer and "new "GSK. The latter have been unloading at around the 335 level, putting a cap on the SP here. Pfizer ( see above) have now gone for a " bazooka" sale. The effect on the SP here must IMV be negative, we will see at the open today. In the longer term , assuming the Pfizer deal gets away fully, is to leave a sound , though still heavily indebted , company with a range of valuable products, which after the dust has settled, I may invest in. Best wishes to all holders, today WILL be bumpy.
Started: Winstanley, 16 Mar 2024 08:55
Last post: Winstanley, 16 Mar 2024 08:55
It's good to see R&D in this. What Partnerships is Tamara thinking of?
' Women’s health is a sizeable growth opportunity and it’s fair to say that it’s been overlooked in the past – by both the public and private sectors. That’s something we want to change as part of our broader health inclusivity ambition and by working through our purposeful brands. To drive systemic change however, partnerships need to be forged across the entire health ecosystem, and there’s a critical role we can play in that.'
https://www.lbbonline.com/news/why-healthcare-giant-haleon-is-taking-womens-pain-seriously/
Started: meoryou, 25 Jan 2024 09:12
Last post: meoryou, 25 Jan 2024 09:12
Alliance News) - Haleon PLC on Thursday it has agreed to sell the ChapStick lip balm brand to Suave Brands Co for around USD430 million in cash.
The Surrey, England-based consumer healthcare company said it will also receive a passive minority interest in Suave Brands, which is a portfolio company of Yellow Wood Partners.
At the time of entering into the binding agreement, Haleon said this minority interest was valued at approximately USD80 million.
See RNS
Started: markbantam, 21 Jan 2024 10:01
Last post: markbantam, 21 Jan 2024 10:01
Share price rise has been limited by investors knowing that GSK are trying to sell to raise funds for aquisition. Hopefully, they will get sell the remaining 4% later in the year and see where it goes from there. Pfizer don't see to be in any hurry to sell their stake.
Jan 17 (Reuters) - GSK (GSK.L), opens new tab has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon (HLN.L), opens new tab, the British drugmaker said on Wednesday.
GSK sold around 300 million shares in Haleon at 326 pence per share, cutting its shareholding in the world's largest standalone consumer healthcare company to 4.2%
https://www.reuters.com/markets/deals/gsk-sell-32-stake-spin-off-haleon-2024-01-16/
Last post: Trickytree55, 15 Jan 2024 13:00
Chairman Dave Lewis to join Clayton,Dubilier Rice as advisor / consultant.
What's happening?
Started: meoryou, 19 Dec 2023 13:34
Last post: Realist1, 25 Dec 2023 10:12
There are large volumes with this share in general but some days are exceptional.
https://uk.finance.yahoo.com/quote/HLN.L/history?p=HLN.L
TrickyTrees
You’re right,I seem to have lost a zero somewhere.
I wonder where I put it?
It is reported as a definite buy.
Someone’s being nice to their self this Christmas
Meoryou - Senior Independent Director has purchased 160,000 Haleon Eqiuty.
He can afford it, unless their is an allocation ?
Just bought 16,000 shares.
That must be at least a slight positive.
See RNS
Started: Alessandro, 20 Nov 2023 17:34
Last post: Trickytree55, 5 Dec 2023 16:29
Surely the journalistic press ramped up this story to force Unilever to bid.
Otherwise Jope would still be leading Unilever.
I'm not so sure that Jope wasn't quietly booted, but allowed to step down to save face, when really he should have been paraded through the streets naked for investors to throw rotten food at.
That said, the real villain of the whole sorry episode was the GUTLESS OAF of a FD - Graeme Pitkethly who's job it was to reign in moronic decisions made by those with little financial knowledge. A spineless yesman promoted way above his very questionable abilities. Fortunately he's going very soon too - but also sadly allowed to leave on his own terms.
Had Unilever lost its marbles when it offered 50 billions pounds for a company with £20B long term liabilities and was GSK so foolish to turn it down? Haleon has to rise 70% to match that offer. Good luck to all the investors. Jope should have been given the boot to come up with that offer.
On the other hand Unilever is regretting turning down a takeover offer for £40 pounds per share when after 5-6 years it is struggling to stay above £40 per share. Crazy times.
Last post: Trickytree55, 15 Nov 2023 14:29
Questor article in Daily Telegraph has updated to say Haleon is solid prospect for rising SP
Started: Mr.Picky, 2 Nov 2023 09:43
Last post: Mr.Picky, 2 Nov 2023 09:43
I listened to the Webcast following the statement. Oh gosh it was boring, listening to Tobias Hestler (CFO) drone on about Sensodyne, Panadol or Centrum sales in different global markets, some where they kept pace with inflationary cost and others where they didn't. All to say in the end that they were still on target to achieve their forecast for FY 2023 the Company continues to expect:-
Organic revenue growth to be 7-8%
Adjusted operating profit growth to be 9-11% constant currency
Net interest expense of c.£350m
Adjusted effective tax rate of 23-24%
Not surprised the shares fell on the results. If their old parent company (GSK) fell when it announced a profit upgrade yesterday why should HLN rise today? (Watch out for a weakening US Dollar; this will hit their targets on the downside.)
Started: casapinos, 5 Oct 2023 19:14
Last post: casapinos, 6 Oct 2023 07:07
"GSK to sell £900m stake in British consumer goods giant Haleon
GSK is poised to sell its £900m stake in British consumer goods giant Haleon.
The pharmaceutical giant announced on Thursday plans to offload 270m shares in Haleon, equivalent to approximately 2.9pc of the company’s listed stock. "
From today's Telegraph, as I suggested a few months ago, 335 or thereabouts is an upper boundary for HLN as the committed sellers ie GSK and Pfizer are keen to offload their major interest here .
Holders should recognise this and consider their positions accordingly, remembering that GSK and Pfizer between them hold about half of Haleon stock.
Started: Winstanley, 4 Sep 2023 22:58
Last post: Trickytree55, 5 Sep 2023 15:07
The Chairman and CEO are very experienced.
Haleon SP to rise as certain non-essential portfolio brands are sold & Net debt is reduced.
'I think I would say don’t underestimate the transformation from being part of a bigger entity to suddenly being a stand-alone firm'
I think I would say don’t underestimate the transformation from being part of a bigger entity to suddenly being a stand-alone firm
Last post: Trickytree55, 24 Aug 2023 13:55
Ex - Divi day today.
Future is bright for Haleon.
The chairman & CEO work well together.
Good summary
I do wonder if someone like Ulvr or similar might at some time come in and take a strategic holding ( perhaps 10%) just to be at the table in future discussions on brands for sale or if a bid came in.
Not really expecting anything soon ,with all the debt they have, but with the big share overhang someone might be able to get a good deal.
Failing that it’s all about paying down the debt, and waiting on developments on the share overhang.
I’m hoping when that finally happens we can maybe see some of the value the Ulvr bid saw be realised.
I don't hold here so if you choose to see my input as irrelevant , feel free. Nevertheless, as a former holder of both GSK and ULVR I watch this space and I thought I could add some helpful comment on prospects here. The latest figures are broadly positive, revenues up ~10% BUT most of that is price increases and there is less scope for further increases as inflation starts to level out ,margins were in fact down 22%and free cash was ~£370 million .
The problems with which Haleon was saddled at birth still loom large, a huge slew of debt which at the present level of income will be with the company for several years, and two major investors in GSK and Pfizer committed to selling their holdings which are about 50% of the equity . GSK's sale in May at 335p effectively puts a cap on the SP , it is a reasonable assumption that either GSK or Pfizer will unload if/when the SP hits that number again, and exceeding it is highly improbable for the foreseeable future. Additionally I learn that both companies are trying to pressure HLN to indemnify them against any costs arising out of the Zantac litigation . IMV that is an appalling abdication of responsibility by both boards and lowers my already poor opinion of Emma Walmsley.
It seems that HLN are trying to fund debt reduction by selling off some of their brands, yesterday's Times mentions Nicotinell and ChapStick. So in summary, I don't see HLN's SP moving up much and I see little prospect of significant divis for a significant time.
I don't do investment advice , so draw your own conclusions.
Started: SussexEngineer, 2 Aug 2023 07:46
Last post: Trickytree55, 2 Aug 2023 15:34
All today with factors affecting stock market.
Downgrading on USA by Fitch to AA+ & BOE Borrowing rate increase to 5.25% tomorrow.
Good buying oppo.
And yet again another company punished for good results by sp dropping.
So just bought some more.
Yesterday analysts were expecting revenue at £5,687m and an adjusted EBITDA of £1,316m. Todays actual results show a revenue of £5,738m and EBITDA of £1,406m. As this is above market expectations, by about 1% and 7% respectively, I would expect this to result in an uprate of the SP.
Started: Mulder, 2 Aug 2023 11:34
Last post: Mulder, 2 Aug 2023 11:34
When Unilever and Reckitt are in the high teens.
Started: travesties, 29 Jun 2023 09:03
Last post: Trickytree55, 28 Jul 2023 13:21
Good to see on UK TV Channels its products - ensures public are aware of Haleon.
The SP has been heading north.
Price of $800 million mentioned, so that could be another slice of debt paid off.
Time will tell
Haleon is notifying interested businesses it is considering Nicotinell brand of nicotine gum, patches and lozenges to
be sold.
SP may go north.
Had these shares for a while thanks to a big investment in GSK. In our house we've stopped buying any of the top "brands" unless they are the cheapest. As budgets tighten with the calamity of rising mortgages and food inflation I expect many others will start to cut back. Yet Haleon has been quite resilient so far. I find it hard to think of this stock as a defensive play so I'm thinking of selling out, perhaps at 340p+. Am I missing something?